What is the differential diagnosis and appropriate workup and management for low serum iron, high ferritin, and low total iron‑binding capacity?

Differential Diagnosis and Management of Low Iron, High Ferritin, and Low TIBC

This laboratory pattern—low serum iron, high ferritin, and low TIBC—indicates anemia of chronic disease (inflammatory anemia) with functional iron deficiency, where iron is sequestered in storage sites by hepcidin and unavailable for erythropoiesis despite adequate or elevated total body iron stores. 1, 2

Understanding the Laboratory Pattern

• Low serum iron reflects insufficient circulating iron available for red blood cell production 2
• High ferritin signals both iron sequestration in reticuloendothelial macrophages and an acute-phase inflammatory response 1, 2
• Low TIBC (or low transferrin) indicates chronic inflammation suppressing hepatic transferrin synthesis, distinguishing this from absolute iron deficiency where TIBC is typically elevated 2, 3
• This combination is pathognomonic for anemia of chronic disease with functional iron deficiency, where hepcidin activation traps iron in storage sites making it unavailable for hemoglobin synthesis 1, 2

Immediate Diagnostic Algorithm

Step 1: Calculate Transferrin Saturation and Confirm the Pattern

• Calculate TSAT = (serum iron ÷ TIBC) × 100% 4
• TSAT <20% confirms iron-deficient erythropoiesis regardless of ferritin level 2, 4
• The combination of TSAT <20% with ferritin 100–300 ng/mL specifically defines functional iron deficiency in chronic disease states 2, 4
• Ferritin >100 ng/mL with low TIBC and low iron excludes absolute iron deficiency; this pattern indicates inflammation-driven iron sequestration 1, 2

Step 2: Measure Inflammatory Markers

• Check C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to confirm active inflammation 2
• Elevated CRP/ESR confirms that ferritin elevation reflects inflammation rather than true iron overload 2, 5

Step 3: Obtain Complete Blood Count

• Assess hemoglobin, MCV, and reticulocyte count to determine anemia severity and red-cell indices 2, 6
• MCV is typically normal (normocytic) in pure anemia of chronic disease, but may become low (microcytic) when true iron deficiency co-exists 2

Differential Diagnosis: Underlying Causes to Investigate

Chronic Inflammatory Conditions (Most Common)

• Chronic kidney disease (CKD): anemia prevalence increases dramatically when eGFR <30 mL/min/1.73m² 2
• Chronic heart failure (CHF): iron deficiency prevalence 37–61%, defined by ferritin <100 μg/L or TSAT <20% 2, 6
• Inflammatory bowel disease (IBD): iron deficiency prevalence 13–90%; ferritin up to 100 μg/L may still indicate deficiency 2, 6
• Active malignancy: iron deficiency prevalence 18–82% 6
• Rheumatologic diseases (rheumatoid arthritis, systemic lupus erythematosus) 2

Occult Blood Loss with Concurrent Inflammation

• In men and postmenopausal women, gastrointestinal investigation (upper endoscopy and colonoscopy) is mandatory to exclude occult malignancy as a source of chronic blood loss 2
• Screen for celiac disease with tissue transglutaminase IgA antibodies; celiac disease accounts for 3–5% of iron-deficiency cases 2
• Test for Helicobacter pylori infection (stool antigen or urea-breath test) because the organism impairs iron absorption 2

Rare Inherited Disorders

• Ferroportin disease (HH type 4A): loss-of-function mutations cause iron retention in macrophages with elevated ferritin, low-to-normal TSAT, and low tolerance to phlebotomy 1
• Aceruloplasminemia (ACP): absent or very low serum ceruloplasmin with low serum copper and iron, high ferritin, and increased hepatic iron; presents with diabetes, retinal degeneration, and neurodegeneration in the fourth to fifth decade 1
• Primary defective iron-reutilization syndrome: hypochromic-microcytic anemia with low serum iron, low-to-normal TIBC, high ferritin, and increased bone marrow iron without ringed sideroblasts; responds to danazol therapy 7

Treatment Algorithm

Oral Iron is Ineffective in This Pattern

• Oral iron supplementation will not work because hepcidin-mediated blockade of intestinal iron absorption prevents oral iron uptake in functional iron deficiency 2
• Even high-dose oral iron (200 mg elemental iron daily) cannot overcome hepcidin inhibition when ferritin is elevated and inflammation is present 2

Intravenous Iron is First-Line Therapy

• Intravenous iron (ferric carboxymaltose, iron sucrose, or low-molecular-weight iron dextran) bypasses hepcidin-mediated intestinal blockade and directly delivers iron to bone marrow 2, 6
• Specific indications for IV iron in this pattern:
  • Chronic kidney disease with eGFR <30 mL/min/1.73m²
  • Heart failure (NYHA class II–III) with ferritin <100 ng/mL or ferritin 100–300 ng/mL plus TSAT <20%
  • Active inflammatory bowel disease
  • Confirmed malignancy with anemia 2, 6
• Ferric carboxymaltose 15 mg/kg (maximum 1000 mg per dose) produces reticulocytosis within 3–5 days and yields a mean hemoglobin increase of ≈8 g/L over 8 days 2

Target TSAT ≥20% After Iron Repletion

• Maintain TSAT ≥20% to ensure adequate iron availability for erythropoiesis 2, 4
• Do not measure iron parameters within 4 weeks of IV iron infusion because circulating iron interferes with assay accuracy 4
• Re-assess iron studies 4–8 weeks after the last IV iron dose 2, 4

Consider Erythropoiesis-Stimulating Agents (ESAs) if IV Iron Fails

• If no hemoglobin response to IV iron occurs, consider ESAs with continued iron supplementation, particularly in CKD or heart failure 2
• ESAs require ongoing iron supplementation; maintaining TSAT >20% is essential for effective ESA response 2

Treat the Underlying Inflammatory Condition

• Failure to identify and treat the underlying chronic inflammatory disease results in ineffective anemia management and persistent treatment failure 2
• Age-appropriate cancer screening should be performed to rule out malignancy as an underlying cause 2

Monitoring and Follow-Up

• Expected hemoglobin response: increase of 1–2 g/dL within 4–8 weeks of IV iron therapy 2
• Repeat CBC and iron studies (ferritin, TSAT) 4–8 weeks after the last IV iron infusion 2, 4
• In patients with ongoing chronic inflammation, repeat iron studies every 4–8 weeks to detect and treat iron deficiency before anemia develops 2

Critical Pitfalls to Avoid

• Do not assume high ferritin indicates iron overload; in inflammatory states, elevated ferritin reflects inflammation-driven iron sequestration, not excess total body iron 2, 5
• Do not prescribe oral iron in this pattern; it provides no therapeutic benefit and exposes patients to unnecessary gastrointestinal adverse effects 2
• Do not rely solely on ferritin to exclude iron deficiency; TSAT is the key parameter for assessing iron availability for erythropoiesis in inflammatory conditions 2, 4
• Do not delay endoscopic evaluation in men and postmenopausal women; gastrointestinal malignancy can present solely with anemia of chronic disease 2
• Do not overlook celiac disease screening (3–5% prevalence in iron-deficiency cases); missing this diagnosis leads to treatment failure 2
• Normal TIBC does not exclude iron deficiency; it must be interpreted alongside ferritin, serum iron, and inflammatory markers 2
• In hemodialysis patients, ferritin >500 ng/mL with ISAT <25% is more strongly associated with inflammation than with iron stores, and this paradoxical combination predicts higher mortality 5, 8